peptide,mhc_binding,expression_tpm,evasion_features,evasion_susceptibility,evasion_mechanisms,evasion_resistance_score
YLQPRTFLL,"{'HLA-A*02:01': {'binding_score': 0.8, 'strong_binder': True}}",8.5,"{'conservation_score': 0.631083826361479, 'mutation_frequency': 0.14222222222222222, 'mhc_binding_strength': 0.8, 'expression_level': 0.85, 'tissue_specificity': 0.1961195276809846, 'immunodominance': 0.68, 'structural_accessibility': 0.7427131179852576}",0.024369551889677727,"{'immunosuppression': {'susceptibility': 0.31999999999999995, 'resistance_strategies': ['checkpoint_inhibitors', 'adjuvants']}, 'regulatory_t_cells': {'susceptibility': 0.1961195276809846, 'resistance_strategies': ['treg_depletion', 'th1_polarization']}, 'mhc_downregulation': {'susceptibility': 0.8, 'resistance_strategies': ['mhc_ii_targeting', 'nk_cell_activation']}}",0.5464327233211311
KIADYNYKL,"{'HLA-A*02:01': {'binding_score': 0.7, 'weak_binder': True}}",12.3,"{'conservation_score': 0.4760022988414278, 'mutation_frequency': 0.14222222222222222, 'mhc_binding_strength': 0.7, 'expression_level': 1, 'tissue_specificity': 0.6654039478780134, 'immunodominance': 0.861, 'structural_accessibility': 0.35124391646901076}",0.07416435668612553,"{'immunosuppression': {'susceptibility': 0.139, 'resistance_strategies': ['checkpoint_inhibitors', 'adjuvants']}, 'regulatory_t_cells': {'susceptibility': 0.6654039478780134, 'resistance_strategies': ['treg_depletion', 'th1_polarization']}, 'mhc_downregulation': {'susceptibility': 0.7, 'resistance_strategies': ['mhc_ii_targeting', 'nk_cell_activation']}}",0.42589562059501906
SLYNTVATL,"{'HLA-A*02:01': {'binding_score': 0.9, 'strong_binder': True}}",15.2,"{'conservation_score': 0.7221856616638138, 'mutation_frequency': 0.14222222222222222, 'mhc_binding_strength': 0.9, 'expression_level': 1, 'tissue_specificity': 0.290055585939509, 'immunodominance': 1, 'structural_accessibility': 0.4769215970220856}",0.02881762538004943,"{'immunosuppression': {'susceptibility': 0, 'resistance_strategies': ['checkpoint_inhibitors', 'adjuvants']}, 'regulatory_t_cells': {'susceptibility': 0.290055585939509, 'resistance_strategies': ['treg_depletion', 'th1_polarization']}, 'mhc_downregulation': {'susceptibility': 0.9, 'resistance_strategies': ['mhc_ii_targeting', 'nk_cell_activation']}}",0.5270338421166377
GILGFVFTL,"{'HLA-A*02:01': {'binding_score': 0.6, 'weak_binder': True}}",6.8,"{'conservation_score': 0.6286427884772484, 'mutation_frequency': 0.15333333333333332, 'mhc_binding_strength': 0.6, 'expression_level': 0.6799999999999999, 'tissue_specificity': 0.5678230370415542, 'immunodominance': 0.408, 'structural_accessibility': 0.3406170562522623}",0.04430593788472872,"{'immunosuppression': {'susceptibility': 0.5920000000000001, 'resistance_strategies': ['checkpoint_inhibitors', 'adjuvants']}, 'regulatory_t_cells': {'susceptibility': 0.5678230370415542, 'resistance_strategies': ['treg_depletion', 'th1_polarization']}, 'mhc_downregulation': {'susceptibility': 0.6, 'resistance_strategies': ['mhc_ii_targeting', 'nk_cell_activation']}}",0.5202569670680539
